サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

医療機器リーダーシリーズ:インビトロ診断(IVD)トップ企業2017-2027

レポート概要

インビトロ診断(IVD)業界の企業は今後どのような可能性を秘めているのでしょうか。このレポートは主要なIVD企業の2027年までの見通しを示します。Visiongainの予測によると、世界のIVD市場は2016年における618億5,000万ドルのレベルから2027年までには1,229億ドルに拡大すると予想され、2016-2027年の推定CAGRは5.4%となります。

このレポートはIVD市場全体とその主要セグメントについて2027年までの予測を示します:

・ ポイントオブケア (POC) 検査
・ 臨床化学
・ 免疫化学
・ 血液学的診断
・ 微生物学的用途
・ 遺伝子検査エージェント
・ その他の製品

レポート詳細

目次

Table of Contents

1. Report Overview
1.1 How This Report Delivers Information
1.2 Main Questions This Report Answers
1.3 Who is This Report For?
1.4 Methods of Research and Analysis
1.5 Frequently Asked Questions (FAQs)
1.6 Some Related Reports
1.7 About Visiongain

2. An Introduction to In Vitro Diagnostics
2.1 The In Vitro Diagnostics Market
2.1.1 The In Vitro Diagnostics Market in 2017
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.3 Classifying In Vitro Diagnostics
2.3.1 The US Classification
2.3.2 The EC (European Commission) Classification
2.3.3 Regulatory Issues in the IVD Market
2.3.3.1 Regulation of IVD Tests
2.3.3.2 Lack of Clarity Can be Costly
2.4 Types of IVD Test
2.4.1 Point of Care Diagnostics
2.4.2 Clinical Chemistry
2.4.3 Microbiology
2.4.3.1 Regulatory Differences with IVD Microbiology Tests
2.4.4 Haematology
2.4.5 Immunochemistry
2.4.6 Genetic Testing
2.5 The IVD Market: Overall Revenue Forecast to 2027
2.5.1 Market Drivers, 2016-2027
2.5.2 Market Restraints, 2016-2027
2.5.3 Future of the IVD Industry
2.6 Company Comparison
2.6.1 Fragmented Market
2.6.2 IVD Market: Leading Manufacturers in 2016

3. The Leading US In Vitro Diagnostic Companies, 2016-2027
3.1 Danaher
3.1.1 Sales and Recent Performance Analysis
3.1.2 Life Sciences and Diagnostics
3.1.3 Key Products
3.1.4 Danaher Manufacturing Capabilities
3.1.5 Danaher IVD Segment: Strengths and Challenges
3.1.6 Danaher’s Life Sciences and Diagnostics Revenues
3.1.6.1 IVD Revenue Forecast, 2016-2027
3.1.7 Recent Mergers and Acquisition (M&A) Activity
3.2 Abbott Laboratories
3.2.1 Sales and Recent Performance Analysis
3.2.2 Abbott: Diagnostics Segment
3.2.2.1 In Vitro Diagnostics Products
3.2.3 Abbott IVD Segment: Strengths and Challenges
3.2.4 Abbott Diagnostics Historical Revenues, 2013-2015
3.2.5 IVD Revenue Forecast, 2016-2027
3.2.6 Recent M&A Activity and Strategic Collaborations
3.2.6.1 Collaboration with GSK
3.2.6.2 Collaboration with Merck
3.2.6.3 Acquisition of STARLIMS Technologies
3.2.6.4 Acquisition of Ibis Biosciences, Inc.
3.2.7 Plans to Separate into Two Publicly Traded Companies
3.3 Johnson & Johnson (J&J)
3.4 Bio-Rad
3.4.1 Sales and Recent Performance Analysis
3.4.2 Clinical Diagnostics
3.4.2.1 In Vitro Diagnostics
3.4.3 IVD Revenue 2015
3.4.4 IVD Revenue Forecast, 2017-2026
3.4.5 Recent M&A Activity and Strategic Collaborations
3.4.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
3.5 Becton Dickinson
3.5.1 Global Presence
3.5.2 Distribution
3.5.3 R&D
3.5.4 Sales and Recent Performance Analysis
3.5.4.1 Historical Sales Performance Analysis
3.5.5 BD Diagnostics Revenue
3.5.6 IVD Revenue Forecast, 2017-2027
3.5.7 Recent M&A Activity and Strategic Collaborations
3.6 Thermo Fisher Scientific
3.6.1 Historical Sales and Recent Performance Analysis
3.6.2 Clinical Diagnostics
3.6.3 Key Products
3.6.4 Thermo Fisher’s Manufacturing Capabilities
3.6.5 Thermo Fisher’s Diagnostics Revenues
3.6.6 IVD Revenue Forecast 2016-2027
3.6.7 Recent Mergers and Acquisition Activity
3.6.7.1 Acquisition of Dionex and Phadia

4. The Leading European In Vitro Diagnostic Companies, 2016-2027
4.1 Roche
4.1.1 Global Presence
4.1.2 Sales and Recent Performance Analysis
4.1.3 Roche Diagnostics
4.1.4 R&D Capabilities
4.1.5 Growing Portfolio of Diagnostic Products
4.1.5.1 Exploring Strategies in the Neurological Sector
4.1.6 IVD Revenue Forecast 2016-2027
4.1.7 Recent M&A Activity and Strategic Collaborations
4.1.7.1 Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics
4.2 Siemens
4.2.1 Sales and Recent Performance, 2015
4.2.2 Siemens Healthcare
4.2.2.1 Siemens Diagnostics
4.2.2.2 Outperforming the Market
4.2.2.3 In Vitro Diagnostics
4.2.3 IVD Revenue Forecast 2016-2027
4.2.4 Recent M&A Activity and Strategic Collaborations
4.2.4.1 Partnership with ViiV Healthcare
4.2.4.2 Partnership with Tocagen
4.3 bioMérieux
4.3.1 Sales and Recent Performance, 2015
4.3.2 IVD Revenue Forecast 2016-2027
4.3.3 Recent M&A Activity and Strategic Collaborations
4.3.3.1 Partnership with GSK
4.3.3.2 Partnership with Ipsen
4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
4.3.3.4 Collaboration with Hospices Civils de Lyon
4.3.3.5 Acquisition of ARGENE
4.3.3.6 Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2016-2027
5.1 Sysmex
5.1.1 Global Presence and Distribution
5.1.2 Sales and Recent Performance Analysis
5.1.3 Sysmex Diagnostics
5.1.4 IVD Revenue Forecast 2016-2027
5.1.5 Recent M&A Activity and Strategic Collaborations
5.1.5.1 Acquisition of Katakura’s Research Institute of Biological Science
5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
5.2 Arkray
5.2.1 Global Presence
5.2.2 R&D
5.2.3 IVD Product Portfolio
5.2.4 Sales and Recent Performance Analysis
5.2.5 IVD Revenue Forecast 2016-2027

6. Emerging In Vitro Diagnostic Companies, 2017
6.1 Pipeline and Other Companies: An Overview, 2017
6.2 Other Prominent In Vitro Diagnostic Players
6.3 Dako (Agilent Technologies)
6.3.1 Sales and Recent Performance Analysis
6.3.2 M&A Activity and Other Key Developments
6.4 Genomic Health
6.4.1 Sales and Recent Performance Analysis
6.4.2 R&D Capabilities
6.4.2.1 TAILORx Clinical Trial
6.4.2.2 RxPonder Trial
6.4.2.3 Partnership with Oncomed
6.5 Laboratory Corporation of America (LabCorp)
6.5.1 Sales and Recent Performance Analysis
6.5.2 In Vitro Diagnostics
6.6 Recent M&A Activity and Other Key Developments
6.6.1 Agreement with Medco Health Sciences
6.6.2 Acquisition of Monogram Biosciences
6.6.3 Non-Exclusive License Agreement with Merck
6.6.4 Acquisition of Genzyme Genetics
6.6.5 Partnership with ARCA Biopharma
6.7 MDxHealth
6.7.1 Sales and Recent Performance Analysis, 2015
6.7.2 R&D Capabilities
6.7.3 In Vitro Diagnostics
6.7.3.1 PharmacoMDx
6.7.3.2 PredictMDx for Brain Cancer
6.7.3.3 PredictMDx for Colon Cancer
6.7.3.4 Partnership with GSK
6.8 Myriad Genetics
6.8.1 Sales and Recent Performance Analysis
6.8.2 R&D Capabilities
6.8.3 In Vitro Diagnostics
6.8.3.1 Myriad RBM
6.8.4 M&A Activity and Recent Partnerships
6.8.4.1 Agreement with BioMarin Pharmaceutical
6.8.4.2 Acquisition of Myriad RBM
6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
6.8.4.4 Agreement with Cephalon
6.8.4.5 Agreement with PharmaMar
6.9 QIAGEN
6.9.1 Sales and Recent Performance Analysis
6.9.2 Continued Expansion in the Emerging Markets
6.9.3 R&D Capabilities
6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
6.9.4 Recent M&A Activity and Other Developments
6.9.4.1 Acquisition of Cellestis Ltd.
6.9.4.2 Acquisition of Ipsogen
6.9.4.3 Partnership with Pfizer
6.9.4.4 Partnership with Eli Lilly
6.9.4.5 Acquisition of SABiosciences Corporation
6.9.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester)
6.9.4.7 Acquisition of Explera s.r.l

7. Conclusions
7.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
7.2 Big Pharma Dominated the IVD Market in 2015
7.3 The Rise of ‘Generic Medical Devices’
7.4 What Will Succeed in the IVD Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2027

Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

Table of Figures
Figure 2.1 IVD Market ($bn) by Class 2017
Figure 2.2 IVD: Overall Market ($bn) Forecast , 2016, 2017, 2021 & 2027
Figure 2.3 IVD Market: Drivers and Restraints, 2016-2027
Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2016
Figure 2.5 Leading Companies in the IVD Industry: Market Shares (%), 2016
Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2015
Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2015
Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.4 Danaher: IVD Market Share (%), 2016-2027
Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2015
Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2015
Figure 3.7 Abbott IVD Historical Performance 2012-2015: Revenue ($bn), AGR (%)
Figure 3.8 Abbott: Revenues ($bn) by Region, 2015
Figure 3.9 Abbott: Revenue Shares (%) by Region, 2015
Figure 3.10 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.11 Abbott: IVD Market Share (%), 2016-2027
Figure 3.12 Bio-Rad: Historical Diagnostics Revenues ($bn), AGR (%), 2013-2015
Figure 3.13 Bio-Rad: Revenue Shares (%) by Business Segment, 2015
Figure 3.14 Bio-Rad: Revenue Shares (%) by Region, 2015
Figure 3.15 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2016-2027
Figure 3.16 Bio-Rad: IVD Market Share (%), 2016-2027
Figure 3.17 BD: Company Revenue ($bn), 2013-2015
Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2016-2027
Figure 3.19 BD: IVD Market Share (%), 2016-2027
Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2013-2015
Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2015
Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 3.23 Thermo Fisher: IVD Market Share (%), 2016-2027
Figure 3.24 Thermo Fisher: Mergers & Acquisitions
Figure 4.1 Roche: Revenues ($bn) by Sector, 2015
Figure 4.2 Roche: Revenue Shares (%) by Sector, 2015
Figure 4.3 Roche Diagnostics: Revenue Shares (%) by Region, 2015
Figure 4.4 Roche Diagnostics: Revenues ($bn) by Sector, 2015
Figure 4.5 Roche Diagnostics: Revenue Shares (%) by Sector, 2015
Figure 4.6 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
Figure 4.7 Roche: IVD Market Share (%), 2016-2027
Figure 4.8 Siemens: Revenue Shares (%) by Sector, 2015
Figure 4.9 Siemens Healthcare: Revenue Shares (%) by Region, 2015
Figure 4.10 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2016-2027
Figure 4.11 Siemens: IVD Market Share (%), 2015-2027
Figure 4.12 bioMérieux: Revenue ($bn) by Sector, 2015
Figure 4.13 bioMérieux: Revenue Shares (%) by Sector, 2015
Figure 4.14 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2015
Figure 4.15 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2015
Figure 4.16 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
Figure 4.17 bioMérieux: IVD Market Share (%), 2016-2027
Figure 5.1 Sysmex: Revenues ($m) by Sector, 2015
Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2015
Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2015
Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 5.5 Sysmex: IVD Market Share (%), 2016-2027
Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
Figure 5.7 Arkray: IVD Market Share (%), 2015-2027
Figure 6.1 Aglient: Revenue ($bn) by Sector, 2015
Figure 6.2 Dako: Revenue Shares (%) by Sector, 2015
Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2011-2015
Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2011-2015
Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2011-2015
Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2015
Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2016
Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2015
Figure 6.11 Myriad: Historical Net Revenues ($m), 2012-2016
Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2016
Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2016
Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2016
Figure 6.15 Myriad: Historical R&D Investments ($m), 2012-2016
Figure 6.16 QIAGEN: Historical Revenue ($m), Net Income ($m), 2011-2015
Figure 6.16 QIAGEN: Revenues ($m) by Customer Class, 2015
Figure 6.17 QIAGEN: Revenue Shares (%) by Customer Class, 2015
Figure 6.18 QIAGEN: Revenue Shares (%) by Region, 2015
Figure 6.19 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2015
Figure 7.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2016-2027
Figure 7.2 Leading Market Segment: Revenue ($bn) Forecasts, 2016-2027

List of Tables
Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2016-2017
Table 2.2 Advantages and Disadvantages of POC Diagnostics
Table 2.3 IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2016, 2017, 2021 & 2027
Table 2.4 Leading Manufacturers: IVD Market Share (%), 2016
Table 2.5 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2016
Table 3.1 Danaher: Key Facts, 2016
Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015
Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%) 2013-2015
Table 3.4 Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 3.5 Abbott: Key Facts, 2016
Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015
Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2015
Table 3.8 Abbott: Diagnostics Revenue ($bn), AGR (%), 2013-2015
Table 3.9 Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 3.10 Johnson & Johnson: Key Facts, 2016
Table 3.11 Bio-Rad: Key Facts, 2017
Table 3.12 Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%), 2013-2015
Table 3.13 Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%), 2016-2027
Table 3.14 BD: Key Facts, 2016
Table 3.15 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2015
Table 3.16 BD: Diagnostics Revenue ($bn), AGR(%), 2013-2015
Table 3.17 BD: IVD Revenue Forecast ($bn) Growth (%), CAGR (%), Market Share (%), 2016-2027
Table 3.18 Thermo Fisher: Key Facts, 2016
Table 3.19 Thermo Fisher: IVD Sales ($bn), AGR (%), 2013-2015
Table 3.20 Thermo Fisher: Net Sales ($bn) and Revenue Shares by product segment (%) by Sector, 2015
Table 3.21 Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 4.1 Roche: Key Facts, 2016
Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%), by Region, 2015
Table 4.4 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 4.5 Roche Diagnostics: Marketed Diagnostic Products
Table 4.6 Roche: IVD Revenue ($bn) Forecast, Growth (%), CAGR (%), Market Share (%) Forecast 2016-2027
Table 4.7 Siemens: Key Facts, 2016
Table 4.8 Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 4.9 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2015
Table 4.10 Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 4.11 bioMérieux: Key Facts, 2016
Table 4.12 bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 4.13 bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 4.14 bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 5.1 Sysmex: Key Facts, 2016
Table 5.2 Sysmex: Revenue ($m) by Sector, 2015
Table 5.3 Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 5.4 Arkray: Key Facts, 2016
Table 5.5 Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
Table 6.1 Aglient: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
Table 6.2 Dako: Marketed Diagnostic Products, 2015
Table 6.4 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015
Table 6.5 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2011-2015
Table 6.6 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2015
Table 6.7 Selected List of LabCorp’s Menu of Diagnostic Products, 2015
Table 6.8 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015
Table 6.9 MDxHealth: In Vitro Diagnostics Pipeline, 2016
Table 6.10 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2016
Table 6.11 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2016
Table 6.12 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2016
Table 6.13 Myriad: Biomarker Product Portfolio, 2016
Table 6.14 Myriad: Diagnostic Products, 2016
Table 6.15 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2015
Table 6.16 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2015
Table 6.17 QIAGEN: Selected List of Co-development Projects
Table 6.18 QIAGEN: Selected Marketed Diagnostic Products, 2015
Table 6.19 QIAGEN: Recent M&A Activity
Table 6.22 Other Companies Operating in the IVD Market, 2016
Table 7.1 Leading IVD Manufacturers by Company Type, 2016

発刊日

2016/11/18

体裁

PDF / 185ページ

販売価格

1,999USD

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※オンラインアクセスの有効期限は、レポートの送付後1年です。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

バイオ・ゲノム・再生医療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE